Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
Event: ESC Congress 2023
Topic: Lipid-Lowering Agents
Session: PCSK9 inhibitors and inclisiran
HAUSER-RCT evolocumab in pediatric patients with heterozygous familial hypercholesterolemia
Event: ESC Congress 2020
Topic: Lipid-Lowering Agents
Session: Latest Findings in Cardiovascular Pharmacotherapy
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Event: ESC Congress 2019
Topic: Lipids, Other
Session: Expert Advice - Premature cardiovascular events? Think familial hypercholesterolaemia
Montreal score and coronary artery calcification in the prediction of cardiovascular event in patients with familial hypercholesterolemia
Event: ESC Congress 2019
Topic: Imaging
Session: Lipids
Health related quality of life is not reduced in elder familial hypercholesterolemia patients
Event: ESC Congress 2019
Topic: Stress, Psychosocial and Cultural Aspects of Heart Disease
Session: Tobacco: psychosocial stress
Summary and audience questions and answers
Event: ESC Congress 2019
Topic: Prevention
Session: A deep dive in to guidelines - Combination therapy, a cornerstone in CV risk reduction
Putting the updated ESC/EAS guidelines in to practice - Expert panel discussion
Event: ESC Congress 2019
Topic: Prevention
Session: A deep dive in to guidelines - Combination therapy, a cornerstone in CV risk reduction
Coronary artery calcification is an independent predictor of cardiovascular events in familial hypercholesterolemia
Event: ESC Congress 2017
Topic: Lipids (Epidemiology and Prevention)
Session: Lipids
Advances in the treatment of dyslipidaemias
Event: ESC Congress 2016
Topic: Medical treatment
Session: Current issues in lipidology for the clinician
ESC 365 is supported by
